AveXis, Inc.

Bannockburn,  IL 
United States
  • Booth: 1861, 1751

AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.

For Technical Support with this webpage, please contact support.